Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 925 to 934 of 934 entries
Sorted by: Best Match Show Resources per page
Calcium channel blockers versus other classes of drugs for hypertension.

The Cochrane database of systematic reviews

Zhu J, Chen N, Zhou M, Guo J, Zhu C, Zhou J, Ma M, He L.
PMID: 35000192
Cochrane Database Syst Rev. 2022 Jan 09;1:CD003654. doi: 10.1002/14651858.CD003654.pub6.

BACKGROUND: This is the first update of a review published in 2010. While calcium channel blockers (CCBs) are often recommended as a first-line drug to treat hypertension, the effect of CCBs on the prevention of cardiovascular events, as compared...

Cite
Zhu J, Chen N, Zhou M, et al. Calcium channel blockers versus other classes of drugs for hypertension. Cochrane Database Syst Rev. 2022;1:CD003654doi: 10.1002/14651858.CD003654.pub6.
Zhu, J., Chen, N., Zhou, M., Guo, J., Zhu, C., Zhou, J., Ma, M., & He, L. (2022). Calcium channel blockers versus other classes of drugs for hypertension. The Cochrane database of systematic reviews, 1CD003654. https://doi.org/10.1002/14651858.CD003654.pub6
Zhu, Jiaying, et al. "Calcium channel blockers versus other classes of drugs for hypertension." The Cochrane database of systematic reviews vol. 1 (2022): CD003654. doi: https://doi.org/10.1002/14651858.CD003654.pub6
Zhu J, Chen N, Zhou M, Guo J, Zhu C, Zhou J, Ma M, He L. Calcium channel blockers versus other classes of drugs for hypertension. Cochrane Database Syst Rev. 2022 Jan 09;1:CD003654. doi: 10.1002/14651858.CD003654.pub6. PMID: 35000192; PMCID: PMC8742884.
Copy Download .nbib Format: NLM
Coronary Flow in Patients With Myocardial Bridges, Coronary Fistulae in the Setting of Unstable Non-Obstructive Coronary Disease.

Cureus

Semerdzhieva NE, Denchev S.
PMID: 33728147
Cureus. 2021 Feb 04;13(2):e13130. doi: 10.7759/cureus.13130.

Оbjective Our aim was to describe the difference in epicardial coronary flow at baseline on background anti-ischaemic therapy and following intracoronary glyceryl trinitrate in patients with acute coronary syndrome and non-obstructive coronary disease with and without myocardial bridges and...

Cite
Semerdzhieva NE, Denchev S. Coronary Flow in Patients With Myocardial Bridges, Coronary Fistulae in the Setting of Unstable Non-Obstructive Coronary Disease. Cureus. 2021;13(2):e13130doi: 10.7759/cureus.13130.
Semerdzhieva, N. E., & Denchev, S. (2021). Coronary Flow in Patients With Myocardial Bridges, Coronary Fistulae in the Setting of Unstable Non-Obstructive Coronary Disease. Cureus, 13(2), e13130. https://doi.org/10.7759/cureus.13130
Semerdzhieva, Niya E, and Denchev, Stefan. "Coronary Flow in Patients With Myocardial Bridges, Coronary Fistulae in the Setting of Unstable Non-Obstructive Coronary Disease." Cureus vol. 13,2 (2021): e13130. doi: https://doi.org/10.7759/cureus.13130
Semerdzhieva NE, Denchev S. Coronary Flow in Patients With Myocardial Bridges, Coronary Fistulae in the Setting of Unstable Non-Obstructive Coronary Disease. Cureus. 2021 Feb 04;13(2):e13130. doi: 10.7759/cureus.13130. PMID: 33728147; PMCID: PMC7936646.
Copy Download .nbib Format: NLM
Calcium channel blockers versus other classes of drugs for hypertension.

The Cochrane database of systematic reviews

Zhu J, Chen N, Zhou M, Guo J, Zhu C, Zhou J, Ma M, He L.
PMID: 35000192
Cochrane Database Syst Rev. 2022 Jan 09;1:CD003654. doi: 10.1002/14651858.CD003654.pub6.

BACKGROUND: This is the first update of a review published in 2010. While calcium channel blockers (CCBs) are often recommended as a first-line drug to treat hypertension, the effect of CCBs on the prevention of cardiovascular events, as compared...

Cite
Zhu J, Chen N, Zhou M, et al. Calcium channel blockers versus other classes of drugs for hypertension. Cochrane Database Syst Rev. 2022;1:CD003654doi: 10.1002/14651858.CD003654.pub6.
Zhu, J., Chen, N., Zhou, M., Guo, J., Zhu, C., Zhou, J., Ma, M., & He, L. (2022). Calcium channel blockers versus other classes of drugs for hypertension. The Cochrane database of systematic reviews, 1CD003654. https://doi.org/10.1002/14651858.CD003654.pub6
Zhu, Jiaying, et al. "Calcium channel blockers versus other classes of drugs for hypertension." The Cochrane database of systematic reviews vol. 1 (2022): CD003654. doi: https://doi.org/10.1002/14651858.CD003654.pub6
Zhu J, Chen N, Zhou M, Guo J, Zhu C, Zhou J, Ma M, He L. Calcium channel blockers versus other classes of drugs for hypertension. Cochrane Database Syst Rev. 2022 Jan 09;1:CD003654. doi: 10.1002/14651858.CD003654.pub6. PMID: 35000192.
Copy Download .nbib Format: NLM
The impact of treatment choices on potential drug-drug interactions in hypertensive patients.

British journal of clinical pharmacology

Perić A, Udilović A, Dobrić S, Vezmar Kovačević S.
PMID: 34862631
Br J Clin Pharmacol. 2021 Dec 03; doi: 10.1111/bcp.15168. Epub 2021 Dec 03.

AIMS: The aim of this study was to analyse potential drug-drug interactions (pDDIs) and their potential adverse drug reactions (ADRs) among hypertensive patients. Moreover, we investigated the possibility of reducing pDDIs with different treatment choices.METHODS: This was a cross-sectional...

Cite
Perić A, Udilović A, Dobrić S, et al. The impact of treatment choices on potential drug-drug interactions in hypertensive patients. Br J Clin Pharmacol. 2021;doi: 10.1111/bcp.15168.
Perić, A., Udilović, A., Dobrić, S., & Vezmar Kovačević, S. (2021). The impact of treatment choices on potential drug-drug interactions in hypertensive patients. British journal of clinical pharmacology, . https://doi.org/10.1111/bcp.15168
Perić, Aneta, et al. "The impact of treatment choices on potential drug-drug interactions in hypertensive patients." British journal of clinical pharmacology vol. (2021). doi: https://doi.org/10.1111/bcp.15168
Perić A, Udilović A, Dobrić S, Vezmar Kovačević S. The impact of treatment choices on potential drug-drug interactions in hypertensive patients. Br J Clin Pharmacol. 2021 Dec 03; doi: 10.1111/bcp.15168. Epub 2021 Dec 03. PMID: 34862631.
Copy Download .nbib Format: NLM
Evaluation of the key prescription sequence symmetry analysis assumption using the calcium channel blocker: Loop diuretic prescribing cascade.

Pharmacoepidemiology and drug safety

Vouri SM, Morris EJ, Usmani SA, Reise R, Jiang X, Pepine CJ, Manini TM, Malone DC, Winterstein AG.
PMID: 34553438
Pharmacoepidemiol Drug Saf. 2022 Jan;31(1):72-81. doi: 10.1002/pds.5362. Epub 2021 Oct 06.

OBJECTIVES: To evaluate the prescription sequence symmetry analysis assumption regarding balance between marker drug (i.e., medication used to treat a drug-induced adverse event) initiation rates before and after initiation of an index drug (i.e., medication that is potentially associated...

Cite
Vouri SM, Morris EJ, Usmani SA, et al. Evaluation of the key prescription sequence symmetry analysis assumption using the calcium channel blocker: Loop diuretic prescribing cascade. Pharmacoepidemiol Drug Saf. 2021;31(1):72-81doi: 10.1002/pds.5362.
Vouri, S. M., Morris, E. J., Usmani, S. A., Reise, R., Jiang, X., Pepine, C. J., Manini, T. M., Malone, D. C., & Winterstein, A. G. (2022). Evaluation of the key prescription sequence symmetry analysis assumption using the calcium channel blocker: Loop diuretic prescribing cascade. Pharmacoepidemiology and drug safety, 31(1), 72-81. https://doi.org/10.1002/pds.5362
Vouri, Scott M, et al. "Evaluation of the key prescription sequence symmetry analysis assumption using the calcium channel blocker: Loop diuretic prescribing cascade." Pharmacoepidemiology and drug safety vol. 31,1 (2022): 72-81. doi: https://doi.org/10.1002/pds.5362
Vouri SM, Morris EJ, Usmani SA, Reise R, Jiang X, Pepine CJ, Manini TM, Malone DC, Winterstein AG. Evaluation of the key prescription sequence symmetry analysis assumption using the calcium channel blocker: Loop diuretic prescribing cascade. Pharmacoepidemiol Drug Saf. 2022 Jan;31(1):72-81. doi: 10.1002/pds.5362. Epub 2021 Oct 06. PMID: 34553438.
Copy Download .nbib Format: NLM
Cluster headache epidemiology including pediatric onset, sex, and ICHD criteria: Results from the International Cluster Headache Questionnaire.

Headache

Schor LI, Pearson SM, Shapiro RE, Zhang W, Miao H, Burish MJ.
PMID: 34841518
Headache. 2021 Nov;61(10):1511-1520. doi: 10.1111/head.14237. Epub 2021 Nov 28.

OBJECTIVE: To validate the diagnoses and to investigate epidemiological data from an international, non-clinic-based, and large (n = 1604) survey of participants with cluster headache.BACKGROUND: There are several limitations in current epidemiological data in cluster headache including a lack...

Cite
Schor LI, Pearson SM, Shapiro RE, et al. Cluster headache epidemiology including pediatric onset, sex, and ICHD criteria: Results from the International Cluster Headache Questionnaire. Headache. 2021;61(10):1511-1520doi: 10.1111/head.14237.
Schor, L. I., Pearson, S. M., Shapiro, R. E., Zhang, W., Miao, H., & Burish, M. J. (2021). Cluster headache epidemiology including pediatric onset, sex, and ICHD criteria: Results from the International Cluster Headache Questionnaire. Headache, 61(10), 1511-1520. https://doi.org/10.1111/head.14237
Schor, Larry I, et al. "Cluster headache epidemiology including pediatric onset, sex, and ICHD criteria: Results from the International Cluster Headache Questionnaire." Headache vol. 61,10 (2021): 1511-1520. doi: https://doi.org/10.1111/head.14237
Schor LI, Pearson SM, Shapiro RE, Zhang W, Miao H, Burish MJ. Cluster headache epidemiology including pediatric onset, sex, and ICHD criteria: Results from the International Cluster Headache Questionnaire. Headache. 2021 Nov;61(10):1511-1520. doi: 10.1111/head.14237. Epub 2021 Nov 28. PMID: 34841518.
Copy Download .nbib Format: NLM
Conflicts over calcium and the treatment of COVID-19.

Evolution, medicine, and public health

Crespi B, Alcock J.
PMID: 33732462
Evol Med Public Health. 2020 Nov 23;9(1):149-156. doi: 10.1093/emph/eoaa046. eCollection 2021.

Several recent studies have provided evidence that use of calcium channel blockers (CCBs), especially amlodipine and nifedipine, can reduce mortality from coronavirus disease 2019 (COVID-19). Moreover, hypocalcemia (a reduced level of serum ionized calcium) has been shown to be...

Cite
Crespi B, Alcock J. Conflicts over calcium and the treatment of COVID-19. Evol Med Public Health. 2020;9(1):149-156doi: 10.1093/emph/eoaa046.
Crespi, B., & Alcock, J. (2021). Conflicts over calcium and the treatment of COVID-19. Evolution, medicine, and public health, 9(1), 149-156. https://doi.org/10.1093/emph/eoaa046
Crespi, Bernard, and Alcock, Joe. "Conflicts over calcium and the treatment of COVID-19." Evolution, medicine, and public health vol. 9,1 (2021): 149-156. doi: https://doi.org/10.1093/emph/eoaa046
Crespi B, Alcock J. Conflicts over calcium and the treatment of COVID-19. Evol Med Public Health. 2020 Nov 23;9(1):149-156. doi: 10.1093/emph/eoaa046. eCollection 2021. PMID: 33732462; PMCID: PMC7717197.
Copy Download .nbib Format: NLM
Self-Reported Antihypertensive Medication Class and Temporal Relationship to Treatment Guidelines.

Hypertension (Dallas, Tex. : 1979)

Egan BM, Yang J, Rakotz MK, Sutherland SE, Jamerson KA, Wright JT, Ferdinand KC, Wozniak GD.
PMID: 34784722
Hypertension. 2022 Feb;79(2):338-348. doi: 10.1161/HYPERTENSIONAHA.121.17102. Epub 2021 Nov 17.

The greater antihypertensive responses to initial therapy with calcium channel blockers (CCBs) or thiazide-type diuretics than renin-angiotensin system blockers as initial therapy in non-Hispanic Black (NHB) adults was recognized in the US High BP guidelines from 1988 to 2003....

Cite
Egan BM, Yang J, Rakotz MK, et al. Self-Reported Antihypertensive Medication Class and Temporal Relationship to Treatment Guidelines. Hypertension. 2021;79(2):338-348doi: 10.1161/HYPERTENSIONAHA.121.17102.
Egan, B. M., Yang, J., Rakotz, M. K., Sutherland, S. E., Jamerson, K. A., Wright, J. T., Ferdinand, K. C., & Wozniak, G. D. (2022). Self-Reported Antihypertensive Medication Class and Temporal Relationship to Treatment Guidelines. Hypertension (Dallas, Tex. : 1979), 79(2), 338-348. https://doi.org/10.1161/HYPERTENSIONAHA.121.17102
Egan, Brent M, et al. "Self-Reported Antihypertensive Medication Class and Temporal Relationship to Treatment Guidelines." Hypertension (Dallas, Tex. : 1979) vol. 79,2 (2022): 338-348. doi: https://doi.org/10.1161/HYPERTENSIONAHA.121.17102
Egan BM, Yang J, Rakotz MK, Sutherland SE, Jamerson KA, Wright JT, Ferdinand KC, Wozniak GD. Self-Reported Antihypertensive Medication Class and Temporal Relationship to Treatment Guidelines. Hypertension. 2022 Feb;79(2):338-348. doi: 10.1161/HYPERTENSIONAHA.121.17102. Epub 2021 Nov 17. PMID: 34784722.
Copy Download .nbib Format: NLM
Coronary Artery Vasospasm Requiring Cardiac Autotransplantation Yet Controlled With Tobacco.

JACC. Case reports

Tran MV, Marceau E, Liu Y, Sallam K, Medina P, Liu C, Sayed N, Muller MD, Liang DH, Chen IY.
PMID: 34401754
JACC Case Rep. 2021 May 26;3(9):1177-1181. doi: 10.1016/j.jaccas.2021.03.018. eCollection 2021 Aug 04.

Coronary artery vasospasm is typically managed through avoidance of triggers and with symptomatic treatments with calcium channel blockers and long-acting nitrates. Here, we report a rare case of medically refractory coronary artery vasospasm associated with genetic predispositions that initially...

Cite
Tran MV, Marceau E, Liu Y, et al. Coronary Artery Vasospasm Requiring Cardiac Autotransplantation Yet Controlled With Tobacco. JACC Case Rep. 2021;3(9):1177-1181doi: 10.1016/j.jaccas.2021.03.018.
Tran, M. V., Marceau, E., Liu, Y., Sallam, K., Medina, P., Liu, C., Sayed, N., Muller, M. D., Liang, D. H., & Chen, I. Y. (2021). Coronary Artery Vasospasm Requiring Cardiac Autotransplantation Yet Controlled With Tobacco. JACC. Case reports, 3(9), 1177-1181. https://doi.org/10.1016/j.jaccas.2021.03.018
Tran, Matthew V, et al. "Coronary Artery Vasospasm Requiring Cardiac Autotransplantation Yet Controlled With Tobacco." JACC. Case reports vol. 3,9 (2021): 1177-1181. doi: https://doi.org/10.1016/j.jaccas.2021.03.018
Tran MV, Marceau E, Liu Y, Sallam K, Medina P, Liu C, Sayed N, Muller MD, Liang DH, Chen IY. Coronary Artery Vasospasm Requiring Cardiac Autotransplantation Yet Controlled With Tobacco. JACC Case Rep. 2021 May 26;3(9):1177-1181. doi: 10.1016/j.jaccas.2021.03.018. eCollection 2021 Aug 04. PMID: 34401754; PMCID: PMC8353556.
Copy Download .nbib Format: NLM
The association between cardiovascular drugs and depression/anxiety in patients with cardiovascular disease: A meta-analysis.

Pharmacological research

Zhang L, Bao Y, Tao S, Zhao Y, Liu M.
PMID: 34890773
Pharmacol Res. 2021 Dec 07;175:106024. doi: 10.1016/j.phrs.2021.106024. Epub 2021 Dec 07.

This study aimed to investigate the association between cardiovascular drugs and depression/anxiety in patients with cardiovascular disease (CVD). This meta-analysis was registered in PROSPERO (International Prospective Register of Systematic Reviews; CRD42020197839) and conducted in accordance with the MOOSE (Meta-analysis...

Cite
Zhang L, Bao Y, Tao S, et al. The association between cardiovascular drugs and depression/anxiety in patients with cardiovascular disease: A meta-analysis. Pharmacol Res. 2021;175:106024doi: 10.1016/j.phrs.2021.106024.
Zhang, L., Bao, Y., Tao, S., Zhao, Y., & Liu, M. (2021). The association between cardiovascular drugs and depression/anxiety in patients with cardiovascular disease: A meta-analysis. Pharmacological research, 175106024. https://doi.org/10.1016/j.phrs.2021.106024
Zhang, Lijun, et al. "The association between cardiovascular drugs and depression/anxiety in patients with cardiovascular disease: A meta-analysis." Pharmacological research vol. 175 (2021): 106024. doi: https://doi.org/10.1016/j.phrs.2021.106024
Zhang L, Bao Y, Tao S, Zhao Y, Liu M. The association between cardiovascular drugs and depression/anxiety in patients with cardiovascular disease: A meta-analysis. Pharmacol Res. 2021 Dec 07;175:106024. doi: 10.1016/j.phrs.2021.106024. Epub 2021 Dec 07. PMID: 34890773.
Copy Download .nbib Format: NLM
Showing 925 to 934 of 934 entries